oncology clinical trials Archives

26 Feb

Articles
No Comments

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

Arc Nouvel is a boutique consulting firm that supports pharmaceutical, biotechnology, and investment clients with end-to-end clinical development solutions, strategic consulting, operational support, and executive coaching across early- to late-phase programs. But the firm’s real advantage lies in the experience...

12 Feb

Articles
No Comments

FDA Accelerated Approval in Oncology: A Strategic Guide for Biopharma

The development of oncology therapeutics is often marked by biological complexity and long timelines required to demonstrate definitive clinical benefit. To address situations in which patients cannot wait for traditional outcome data, the U.S. Food and Drug Administration (FDA) established...

16 Jan

Articles
No Comments

Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early

In oncology drug development, FDA rejection is often perceived as a late-stage failure, an FDA Complete Response Letter (CRL) that arrives after many years of pre-clinical development, years of intense clinical work, heavy capital investment, and deep, persistent patient needs....

14 Jan

Articles
No Comments

6 Oncology Drugs Likely to Receive FDA Approval in 2026: A Clinical and Regulatory Analysis

Each year, the oncology development landscape becomes noisier. Late-stage assets are promoted aggressively, conference headlines amplify early signals, and investor narratives often blur the line between promise and probability. After more than 12 years leading global clinical programs across major...

oncology clinical trials

Who is Arc Nouvel: Dr. Robert Charnas on Regulatory Strategy, Patient-Focused Development, and the Discipline to Stop

FDA Accelerated Approval in Oncology: A Strategic Guide for Biopharma

Why Cancer Drugs Fail FDA Approval: How Clinical Trial Teams Can Prevent Rejection Early

6 Oncology Drugs Likely to Receive FDA Approval in 2026: A Clinical and Regulatory Analysis

Contact us Now

Menu

Contact Us

Follow Us